von Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Therapy

von-Hippel-Lindau Syndrome: Target for Anti-Vascular Endothelial Growth Factor (VEGF) Receptor Therapy Adrian L. Harris The Oncologist, Vol. 5, Suppl 1, 32-36, April 2000 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in the field of Neuro-Oncology and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Understand the molecular basis for von Hippel-Lindau (VHL) Syndrome and renal cancer. Appreciate the complexity of the clinical syndrome and how it is related to different mutations of the VHL gene. Be aware of the many genes regulated by VHL and how they contribute to the cancer phenotype. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: July 10, 2002 Most Recent Review: June 10, 2005* Most Recent Update: July 10, 2003 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.